Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? - Reply

被引：1
|
作者：
Moore, Malcolm J. [1 ]
Au, Heather Jane
Parulekar, Wendy
机构：
[1] Univ Toronto, Princess Margaret Hosp, NCI,Div Med Oncol & Hematol, Canada Clin Trials Grp Gastrointestinal Dis Commi, Toronto, ON, Canada
[2] Queens Univ, NCI, Canada Clin Trials Grp, Kingston, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 28期
关键词：
D O I：
10.1200/JCO.2007.13.1862
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4508 / 4508
页数：1
相关论文
共 50 条
  • [41] Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer
    Smith, Jill P.
    Bingaman, Sandra I.
    Mauger, David T.
    Harvey, Harold H.
    Demers, Laurence M.
    Zagon, Ian S.
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2010, 2 : 37 - 48
  • [42] Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (Reprinted from vol 25, 1960, 2007)
    Moore, Malcolm J.
    Goldstein, David
    Hamm, John
    Figer, Arie
    Hecht, Joel R.
    Gallinger, Steven
    Au, Heather J.
    Murawa, Pawel
    Walde, David
    Wolff, Robert A.
    Campos, Daniel
    Lim, Robert
    Ding, Keyue
    Clark, Gary
    Voskoglou-Nomikos, Theodora
    Ptasynski, Mieke
    Parulekar, Wendy
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) : 4714 - 4720
  • [43] A Phase II Trial of Gemcitabine and Erlotinib (GE) plus Proton Chemotherapy (PCT) and Capecitabine and Oxaliplatin (CapOx) for Locally Advanced Pancreatic Cancer
    Coffman, A. R.
    Hsueh, C. T.
    Hernandez, M.
    Mirshahidi, S.
    Wang, J.
    Solomon, N. L.
    Garberoglio, C. A.
    Reeves, M. E.
    Slater, J. D.
    Yang, G. Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E599 - E600
  • [44] Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis
    Zeng, Minyan
    Feng, Qi
    Lu, Ming
    Zhou, Jun
    Yang, Zuyao
    Tang, Jinling
    ONCOTARGETS AND THERAPY, 2018, 11 : 6633 - 6646
  • [45] Thrombocytosis in patients with pancreatic cancer treated with gemcitabine - does it have clinical significance? Description of 6 cases
    Swieboda-Sadlej, Anna
    Kraj, Leszek
    Krawczyk, Joanna
    Nita, Ewa
    Dwilewicz-Trojaczek, Jadwiga
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (04): : 353 - 355
  • [46] Comorbidity, age and overall survival in patients with advanced pancreatic cancer - Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo
    Vickers, M. M.
    Powell, E. D.
    Asmis, T. R.
    Jonker, D. J.
    Hilton, J. F.
    O'Callaghan, C. J.
    Tu, D.
    Parulekar, W.
    Moore, M. J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (10) : 1434 - 1442
  • [47] Comorbidity and overall survival (OS) in patients with advanced pancreatic cancer (APC): Results from NCIC CTG PA.3-A phase III trial of erlotinib plus gemcitabine (E plus G) versus gemcitabine (G) alone
    Vickers, M. M.
    Powell, E. D.
    Asmis, T. R.
    Jonker, D. J.
    O'Callaghan, C. J.
    Tu, D.
    Parulekar, W.
    Moore, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Can decreasing the serum level of CA19-9 predict the survival benefit of gemcitabine for advanced pancreatic cancer?
    Sawaki, A
    Katsurahara, M
    Okubo, K
    Mizuno, N
    Nakamura, T
    Tajika, M
    Kawai, H
    Toyma, T
    Yamao, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 365S - 365S
  • [49] Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Boeck, S. H.
    Vehling-Kaiser, U.
    Waldschmidt, D.
    Kettner, E.
    Maerten, A.
    Winkelmann, C.
    Klein, S.
    Kojouharoff, G.
    Jung, A.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [50] Phase II clinical trial of nab-paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer
    Jameson, Gayle S.
    Hosein, Peter J.
    Pierce, Erin
    Kamgar, Mandana
    Gordon, Michael S.
    Snyder, Courtney
    Roe, Denise J.
    Wertheim, Betsy C.
    Davey, Marina
    Barrett, Michael T.
    Von Hoff, Daniel D.
    Borazanci, Erkut
    CANCER MEDICINE, 2024, 13 (12):
12345